Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a drug discount website.
Zepbound
Posted inNPR
Quit a GLP-1? Plan to start again? It’s not recommended, but plenty of people do itÂ
A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn’t yet shown the health impacts of cycling on and off the drugs.
Posted inNPR
What does a ‘GLP-1 Friendly’ diet look like? We asked nutritionists
Big food companies are starting to market to people on the powerful new obesity meds with labels that say “GLP-1 Friendly.” Nutritionists help us decode that message.
Posted inNPR
GLP-1 drugs don’t work for everyone. But personalized obesity care in the future might
As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.
Posted inNPR
Brain scientists are seeking weight-loss drugs without the nausea
Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways to solve this problem.
Posted inNPR
White House strikes deals for lower prices on obesity drugs
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some limitations.
Posted inNPR
A new chapter for online sales of obesity drug alternatives tests legal limits
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries.Â
Posted inNPR
Consumers can buy Zepbound direct from the drugmaker if they’ll pay out of pocket
Eli Lilly is offering vials of its obesity drug Zepbound to patients at a discount — but only if they skip their insurance.
Posted inNPR
When online weight-loss drugs are too good to be true
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients.
Posted inNPR
Drugmakers and pharmacists battle over who gets to make obesity drugs
The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from making cheaper copies. They argue they can keep up with demand on their own.
